The complement system is the first line of defense against invading pathogenic microorganisms, including viruses. Not only can viruses and virally infected cells be eliminated by direct lysis (1) but also covalent coating of virions by C3b and C4b can sterically hinder virus binding to receptors and reduce effective viral load. Complement activation can be initiated by recognition of various molecular structures, which leads to activation of a proteolytic cascade. There are three pathways by which complement can be initiated as follows: the classical, the lectin, and the alternative pathway. All pathways result in assembly of C3-convertases whose function is to proteolytically activate C3 into C3b, which is subsequently covalently attached to adjacent surfaces. Deposition of C3b on the activating surface localizes the activation of the complement cascade and leads to formation of a membrane attack complex. Complement also enhances other immune effector mechanisms through opsonization, phagocytosis, and chemoattraction of immune cells (2) . Complement ties the innate immune system to cellular and humoral immune responses and greatly enhances the efficacy of antiviral antibodies in neutralizing and clearing viruses. The importance of the complement system for antiviral defense is emphasized by consistent identification of complement evasion molecules or strategies found for all classes of animal viruses. These strategies are not limited to molecular mimicry as many enveloped viruses additionally hijack host inhibitors during egress (for review see Ref. 3) . Many of the viral complement inhibitors have been identified based on their sequence similarity to the host molecules (4) . These include viral complement inhibitors vaccinia complement control protein (VCP) (C4BP), and factor H (7, 8) . Each CCP domain consists of 60 -70 amino acids, which are stabilized by two disulfide bonds (9, 10) .
Previously we reported that KCP strongly enhanced the decay (decay accelerating activity (DAA)) of the classical C3-convertase, but not the alternative pathway C3-convertase, and also induced factor I (FI)-mediated degradation of activated complement factors C4b and C3b (cofactor activity (CFA)) (11) . Furthermore, we have characterized and modeled the region of KCP that is responsible for heparin binding (12) . We therefore hypothesize that this protein is multifunctional in the context of KSHV biology (11) . First, it provides a mechanism for reducing complement activation during virus infection and reactivation. Second, it may facilitate KSHV attachment and infection of the cell (13) . However, studies of the contribution of KCP to KSHV infection and pathogenesis in vivo are limited by the inability of KSHV to infect non-human primates. RRV, a simian ␥-2 herpesvirus closely related to KSHV, obviates this limitation. Rhesus macaques infected with RRV17577 develop B-cell lymphoproliferative disorders and endothelial cell lesions arguably pathogenetically similar to those found in humans infected with KSHV (14 -17) .
Two strains of RRV (H2695 and 17577) have now been sequenced, and both encode KCP homologs. These proteins were named RCP (6) . Despite predicted high amino acid similarity between most of the proteins encoded by the two RRV strains, their RCP genes differed significantly from each other; RCP from strain 17577 (referred to as RCP-1) consists of 645 amino acids and contains eight CCP domains, whereas RCP from strain H2695 (RCP-H) consists of 395 amino acids and contains four CCP domains (18) , consistent with the four CCP domains found in KCP (19) . Both RCP-1 and RCP-H have a C-terminal transmembrane spanning region, as does KCP. RCP is present on the surface of RRV virions, and rhesus monkeys infected with RRV produce anti-RCP antibodies (19) . Our initial functional studies indicated that RCP is a functional complement inhibitor, because it inhibited deposition of C3b when expressed on CHO cells, coated with rabbit polyclonal anti-CHO antibody, and exposed to human serum (19) . Here, we provide a more detailed functional study of complement inhibition mechanisms for RCP from both H2695 and 17577 strains. Moreover, we assess independently the activity of RCP-1 CCP domains 1-4 (referred to here as RCP 1-4) and CCP domains 5-8 (referred to as RCP 5-8), which appear to have arisen through gene duplication and could represent independent functional units. In this study all complement inhibition mechanisms of RCP were compared with KCP, to support the potential future use of RRV (and RCP) as a model for understanding the contribution of these gammaherpesvirus complement inhibitors to pathogenesis in primates. Furthermore, the study provides novel insight into mechanisms by which viral complement inhibitors exert their inhibitory function.
EXPERIMENTAL PROCEDURES
Proteins-Membrane-bound and soluble RCP proteins were expressed using the same strategy as described previously for KCP (13, 20) . Briefly, soluble proteins were expressed following cloning into expression vectors that added a C-terminal Fc fragment from human IgG1, and membrane-bound proteins were expressed following cloning into an expression vector that added the C-terminal glycosylphosphatidylinositol (GPI) anchor from human decay-accelerating factor (20) . To obtain subclones of RCP-1, namely RCP 1-4 and RCP 5-8, respectively, primers CCP1-4_F ϭ TCTAGAAACGCTGTGCCG-TATAACTGG ϩ CCP1-4_R ϭ GCGGCCGCAGTAACGTC-GTCTTTCTCTGGAG, and CCP5-8_F ϭ ACTAGTGAGAA-AGACGACGTTACTTGTGT ϩ CCP5-8_R ϭ GCGGCCGC-CCTTTCCATTTACTCATTGGG carrying restriction sites for NotI and XbaI were used. CHO cells were transfected using Lipofectin (Invitrogen). Stable transfectants were selected with hygromycin B (Roche Applied Science) and screened for expression of RCP by flow cytometry (membrane-bound RCPs) or Western blotting (soluble proteins with Fc tags), using rabbit antisera described below. For flow cytometry, cells were detached with versene (Invitrogen) and then stained with the respective antiserum diluted 1:100 in binding buffer (140 mM NaCl, 10 mM HEPES, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , pH 7.2), followed by anti-rabbit-fluorescein isothiocyanate polyclonal Ab (Dako) diluted 1:75. Data were collected using FACSCalibur (BD Biosciences) and analyzed with WinMDI 2.8 software. Soluble proteins were purified from conditioned medium by affinity chromatography using protein A-Sepharose, as described for KCP in Ref. 8 , with an additional final step of anion-exchange chromatography. Thus, RCP variants eluted from the protein A-Sepharose were dialyzed against 50 mM Tris-HCl, pH 8.5, and loaded onto Mono Q column connected to Ä kta Explorer system (GE Healthcare). Proteins were eluted with a linear 0 -0.6 M NaCl gradient in 50 mM Tris-HCl, pH 8.5, dialyzed against 50 mM Tris-HCl, pH 8.5, concentrated, and stored at Ϫ80°C. Purified complement proteins C2, C3, C3b, C4, C4b, C5, C6, C7, C8, C9, factor B and D, and properdin were purchased from Complement Technology. C1 was purified from plasma as described (11) and assessed as functionally pure. C3met and C4met, functionally equal to C3b and C4b, respectively, were prepared from purified C3 and C4 as described (21) .
Antibodies-Rabbit antisera recognizing RCP-1 CCP domains 1-2, RCP-1 CCP domains 5-6, and RCP-H CCP1-2 were raised in rabbits as described previously (19) , and they are identified in the text as anti-RCP 1-2, anti-RCP 5-6, and anti-RCP-H, respectively.
Western Blotting-Samples were separated by electrophoresis on 10% (or 7.5% for RCP-1) SDS-polyacrylamide gels and transferred onto polyvinylidene difluoride membrane (Pall) by a semi-dry blotting. Membranes were blocked with quenching buffer as follows: 3% fish gelatin (Nordic) in washing buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM CaCl 2 , 0.1% Tween 20) and then incubated with anti-RCP antisera diluted 1:250 in quenching solution (3% fish gelatin in binding buffer) followed by anti-rabbit horseradish peroxidase (Dako) diluted 1:1000. Blots were developed using 0.5 mg/ml 3,3-diaminobenzidine, 0.6 M NiCl 2 (both from Sigma), 1 mM H 2 O 2 in Tris-buffered saline buffer, pH 8.0.
Hemolytic Assay on Whole Serum-Monkey serum was obtained from rhesus macaques, which were housed and maintained in accordance with United Kingdom Home Office guidelines. Serum was clotted for 30 min at room temperature, placed on ice for 45 min, centrifuged, and immediately frozen in Ϫ70°C. For the classical pathway, sheep erythrocytes were coated with amboceptor (Behring Diagnostics, Inc.) as described (11) and then washed and incubated with human or rhesus macaque sera diluted with DGVB 2ϩ (2.5 mM veronal buffer, pH 7.3, 72 mM NaCl, 140 mM glucose, 0.1% gelatin, 1 mM MgCl 2 , and 0.15 mM CaCl 2 ). Rabbit erythrocytes diluted in Mg 2ϩ -EGTA buffer (2.5 mM veronal buffer, pH 7.3, 70 mM NaCl, 140 mM glucose, 0.1% gelatin, 7 mM MgCl 2 , and 10 mM EGTA) were used to study alternative pathway activity. Sera were first titrated to assess the minimal concentration giving significant readout. These values were found to be 2% for the alternative pathway (human and rhesus macaque sera) and 0.1 and 0.2% for the classical pathway for rhesus macaque and human sera, respectively. In all assays, erythrocytes (25 l of 10 9 /ml for each experimental point) were mixed with sera diluted in pathway-specific buffers containing RCPs or KCP at a final concentration of 0.5 M, incubated for 1 h at 37°C, and the samples centrifuged. Absorbance of supernatant was measured at 405 nm. Readout of samples with no inhibitor added was set as 100%.
C3 Deposition on RCP-expressing CHO Cells-Experiments were performed as described previously (19) . Briefly, CHO cells stably expressing RCP 1-4, RCP 5-8, or KCP were sensitized with anti-hamster lymphocyte antibodies (Sigma) diluted 1:25 in binding buffer, washed twice, incubated with human serum at indicated concentrations, and assayed for C3 deposition.
Binding of RCP to C3b/C4b-Microtiter plates (Maxisorp, Nunc) were coated overnight with C3b (1.0 g/ml) or C4b (0.2 g/ml) diluted in 0.1 M carbonate buffer, pH 9.6. The preparations of C3b and C4b contained only 0.28 and 0.08% of dimers. Plates were blocked with quenching buffer (1.5% fish gelatin in washing buffer: 10 mM Tris-HCl, pH 8.0, 40 mM NaCl, 0.5 mM CaCl 2 , 0.02% Tween 20) , and proteins to be studied were added at concentrations of 0.5 M. After a 60 min incubation at 37°C, plates were washed three times with washing buffer and then incubated with primary antibody (rabbit anti-human IgG, Dako, 1:1000) followed by anti-rabbit horseradish peroxidaseconjugated Ab (Dako) diluted 1:1000 in quenching buffer. The assay was developed with 1,2-phenylenediamine dihydrochloride substrate (Dako), as described previously (22) .
C3b/C4b Degradation Assay-Degradation of C3b/C4b was performed as described previously (22) . Band intensity was measured with a PhosphorImager (FLA3000, FujiFilm) and quantified by MultiGauge software (FujiFilm). The intensity of the ␣Ј chain band was normalized to that of either the ␤ chain (C3b assay) or the ␥ chain (C4b assay).
Convertase Decay Acceleration Assay-Acceleration of decay of the classical and the alternative C3-convertases as well as C5-convertases was measured with hemolytic assays. C3-convertase and C5-convertase complexes were built from purified components on the surface of sheep erythrocytes as described previously (11, 23) . To build up alternative C5 convertase, we used 20-fold excess of factor B and 2-fold more factor D than that described in Ref. 23 . Convertases were treated with a range of RCP concentrations (0.02-0.5 M). The remaining convertases were quantified by incubation with 4% guinea pig serum (C3-convertases) or a mixture of C5-C9 proteins (1 g/ml each) Ϯ C3 (for C5-convertases), all diluted in 40 mM EDTA-GVB buffer (40 mM EDTA, 0.1% gelatin, 3 mM veronal buffer). Released hemoglobin relative to the number of lysed cells was measured at 405 nm with a microtiter plate reader.
Binding to Heparin-Determination of heparin binding was performed as described previously for KCP (12) . Briefly, 1 M of RCPs or KCP was loaded onto a Hi-Trap heparin column (GE Healthcare) and eluted with a 0 -0.5 M NaCl linear gradient. Proteins were detected by measuring absorbance at 214 nm, and the NaCl concentration at the elution peak was calculated using the conductivity values.
Modeling of RCP-H Protein-A homology model of RCP-H was built using the crystallographic structure of CD55 (Protein Data Bank code 1QJV) (24) using the Insight II package and the modules Biopolymer, Homology, and Discover (Accelrys) and ICM (Molsoft LLC). Briefly, the two sequences (RCP and CD55) were aligned and compared, and the sequence identity was found to be 34% with a clear conservation in the core region of CCP domains and complete conservation of the disulfide bonds. Seven small deletions (1-3 residues) were present in the RCP model, and four loops (insertions) had to be built. These steps were accomplished through energy minimization with Discover for deletions (keeping the remainder of the structure fixed) and using loop building utilities from Homology and ICM. In all cases, we decided to select loops originating from other experimental structures than the initial structure and to refine these regions via several rounds of energy minimization with Discover. The final model was then generated after energy minimization of the entire structure. Initially, all the heavy atoms were tethered, and the force constant was lowered to zero at the end of the simulation.
Analysis of the putative heparin-binding regions was performed with the pocket finder utility (25) . Briefly, the expected heparin-binding region of KCP was bombarded with atomic probes of three different types, hydrophobic probe, hydrogen bond donor probe, and hydrogen bond acceptor probe. These probes define the surface area that has a significant binding opportunity for a small to medium size molecular partner. Corresponding computation on the equivalent region of RCP was then performed (Fig. 8B) .
RESULTS

Membrane-bound RCP-1 Fragments Decrease Complement
Activation-Previously we showed that full-length RCP-1 and RCP-H expressed on the surface of CHO cells as GPI-anchored proteins decreased complement activation on these cells measured as deposition of C3b, similar to KCP (19) . In this study we expressed two fragments of RCP-1 encompassing CCP1-4 (RCP 1-4) and CCP5-8 (RCP 5-8), respectively. Expression of the RCP subparts at the surface of transfected CHO cells was confirmed by staining with antisera against CCP1-2 and CCP5-6 of RCP-1 and flow cytometric analyses (Fig. 1A) . Both RCP 1-4 and RCP 5-8 could independently inhibit antibodymediated complement activation (Fig. 1B) implying that they may form independent functional units.
Expression and Purification of Fc-tagged RCP Proteins-To understand the mechanism of RCP-mediated inhibition of complement activation, studies of purified, soluble, and recombinant RCP proteins were performed. The proteins were expressed as Fc fusions to enable their purification. The purity of obtained proteins was confirmed by silver staining (Fig. 2A, 
left panel, RCP 1-4, RCP 5-8, and RCP-H; right panel, RCP-1).
Proteins of interest were also identified by Western blotting, which yielded bands of expected molecular sizes (Fig. 2B) . The specificity of each antibody was confirmed because they only recognized RCP proteins containing the domains against which the antibodies were raised, i.e. RCP 1-4 was recognized only by anti-RCP 1-2 Ab and RCP 5-8 only by anti-RCP 5-6 Ab, and RCP-H was recognized mostly by anti-RCP-H Ab and also weakly by anti-RCP 5-6, indicating weak cross-reactivity (Fig.  2B, left panel) . RCP-1 was recognized by both anti-RCP 1-2 Ab and anti-RCP 5-6 Ab but not anti-RCP-H Ab, as expected (Fig.  2B, right panel) .
RCP and KCP Interfere with Rhesus Macaque and Human Complement-All available assays necessary to study detailed mechanisms of complement inhibition are based on human reagents. Therefore, it was important to test first if RCP affects both human and rhesus macaque complement. All isoforms of RCP as well as KCP exhibited significant inhibition of complement-mediated hemolysis in both species (Fig. 3) . As could be expected, the RCPs were more effective against rhesus than human complement in both pathways. KCP, on the other hand, was less efficient in inhibition of the alternative pathway in rhesus serum (Fig. 3D ) as compared with human serum (B). For the classical pathway, KCP inhibited rhesus complement better (Fig. 3C ), but the difference was less pronounced than for all RCP variants.
RCP Proteins Bind C3b and C4b-Because all known CCP containing complement inhibitors bind activated complement factors C3b and C4b, we investigated the ability of purified RCP-Fc fusion proteins to bind C3b and C4b immobilized in microtiter plates. RCP-Fc fusion proteins were detected with anti IgG1 antibody. RCP-H bound C3b and C4b comparably to KCP, whereas much more full-length RCP-1 was retained by immobilized complement factors despite the fact that equivalent molar amounts of all RCP variants were used (Fig. 4) . Importantly, the binding of shorter fragments of RCP-1 was dramatically reduced to the level where they could hardly be RCP-H, RCP 1-4,and RCP 5-8 were separated by electrophoresis on 10% SDSpolyacrylamide gels under reducing conditions. RCP-1 was run in 7.5% SDS-PAGE. The purity of the proteins was assessed by silver staining (A), whereas Western blotting confirmed identity of all bands (B). A weak cross-reactivity was observed between RCP-H and RCP 5-6 antisera.
detected in the current experimental set up. Nevertheless, low affinity binding of complement inhibitor to C3b/C4b does not exclude functional outcome of the interaction. For example, C4BP binds its main ligand C4b protein with micromolar K D but serves as a very good cofactor in degradation of C4b (21) .
RCP Variants Support Factor I-mediated Degradation of C3b and C4b-To determine the fate of RCP-Fc protein-bound C3b and C4b, the FI-mediated degradation of these complement proteins was measured. Intact C3b is composed of ␣Ј and ␤ chains (Fig. 5A, negative control) . In the presence of a cofactor such as C4BP and FI (positive control), ␣Ј is degraded to 68-, 46-, and 43-kDa fragments. Degradation assays revealed that all RCP proteins efficiently supported FI-mediated cleavage of C3b (Fig. 5C ). The same C3b degradation assay performed for KCP showed that 1.9 M of KCP was required for cleavage of 50% of the ␣-chain of C3b (11) . Here, similar efficiency was observed for RCP 1-4 fragment, whereas RCP-1, RCP-H, and RCP 5-8 were about 2 orders of magnitude more effective. Intact C4b consists of ␣Ј, ␤, and ␥ chains (Fig. 5B, negative  control) . In the presence of C4BP and FI (positive control), the ␣Ј chain was degraded to C4d and ␥-4 fragments, of which only C4d was visible on the radiogram. All RCP variants were similar in their efficiency as cofactors for C4b degradation by FI (Fig.  5D) , comparable with the previously reported efficiency of KCP (50% cleavage at 1.85 M) (11) .
RCP-accelerated Decay of Classical and Alternative C3/C5 Convertases-KCP was reported previously to accelerate decay of the classical but not the alternative C3 convertase (11) . Here, our hemolytic assays revealed that RCP-1 and its fragments accelerated the decay of the classical C3 convertase with almost twice the efficiency of KCP-mediated classical C3 convertase decay (Fig. 6A) . Decay accelerating activity of RCP-H was still measurable; however, it was only half as effective as KCP at 0.25 M concentration.
Unexpectedly, we found that RCP-1 was very effective at accelerating the decay of the alternative C3 convertases (even at a concentration of 0.1 M), whereas RCP-H was very poor (Fig.  6B) . However, the ability of CCP domains 1-4 and 5-8 of RCP-1 to decay alternative C3 convertases was dramatically reduced if tested independently. We have previously shown that both decay acceleration assays are not affected by the Fc tag by itself (11) .
We also investigated the ability of KCP and RCP to accelerate the decay of C5 convertases using the protocol described previously (23) . Briefly, to build the classical (C4b2aC3b) and alternative (C3bBbC3b) C5 convertases, more C3 (alternative convertase) or an additional incubation step with C3 (classical convertase) was employed to deposit excessive C3b on already formed C3 convertases. Target cell lysis was measured following addition of purified C5-C9 components. The highest concentration of complement inhibitors used to study DAA of C3 convertases was examined. RCP-1 disassembled C5 classical . After incubation cell lysis was examined by measuring the absorbance of supernatant at 405 nm, and 100% is referred to readout of sample with no inhibitor added. Data are collected from three independent experiments and presented as means Ϯ S.D. Statistical significance between particular protein and "no inhibitor" readout was assessed by the Student's t test for unpaired data, where * ϭ p Ͻ 0.05; ** ϭ p Ͻ 0.01; *** ϭ p Ͻ 0.001. convertase more effectively than RCP-H and KCP, which can be explained by the fact that RCP-1 has two potential active sites. No C5 classical convertase DAA was observed for shorter subunits of RCP-1 as follows: RCP 1-4 and RCP 5-8 (Fig. 6C) . During the C5 alternative convertase assembly steps, C3 classical convertase employed to deposit C3b could theoretically produce C3b dimers and thus form C5 alternative convertase prematurely (23) . Therefore, to check this possibility and to verify the results of our previous experiment designed to measure alternative C3 convertase activity (Fig. 6B) , we enabled formation of the terminal lytic complex by using purified C5-C9 components in the presence and absence of additional C3. Hemolysis in the presence of additional C3 in the final step of the assay was more than three times higher compared with hemolysis in the absence of C3 (data not shown), thus indicating that the readout for the experiment presented in Fig. 6D shows specific decay of alternative C5 convertase activity and that the previous experiment (Fig. 6B ) measured mostly alternative C3 convertase activity. Interestingly, we obtained results similar to those for the C3 alternative convertase, i.e. full inhibition by RCP-1, strong inhibition by RCP 1-4 and RCP 5-8, and no inhibition by RCP-H and KCP (Fig. 6, B and D) .
RCP, Unlike KCP, Does Not Bind
Heparin-We previously reported that KCP binds to heparin at physiological ionic strength (12) . Using a heparin column, we examined the ability of KCP and RCP proteins to be retained and eluted. Only KCP bound strongly and could be eluted by salt concentrations higher than physiological (peak at 200 mM NaCl). For all RCP variants, most of the loaded material was detected in flow-through (when loaded at 0 mM NaCl), and only modest amounts of RCPs were eluted with the salt gradient, but in all cases at concentrations lower than physiological 140 mM. Elution profiles of KCP and RCP 5-8 (which showed strongest binding out of all RCPs tested in this study) are presented in Fig. 7 , and the remaining elution profiles are not shown.
RCP Differs from KCP in the Structure of the CCP1/CCP2 Interface Region-Previously we have established a three-dimensional homology-based model of KCP (8).
This model allowed the location of amino acids critical for particular complement-related functions (8) as well as for the binding of the negatively charged heparin molecule (12) . Here, we created a structural model for RCP-H (also containing four CCP domains) and investigated the main structural similarities and key amino acid conservations and differences. The RCP-H structural model revealed that the interface between CCP1 and CCP2 lacks some surfaceexposed, positively charged residues, which are present in KCP (Arg-20 and Arg-33) (Fig. 8A) . Moreover, unlike in KCP, there is a loop extension around Ser-133, located at the level of the CCP1-CCP2 linker region of RCP-H (Fig. 8) . This region has been suggested as the heparin-binding site, and these changes may offer an explanation for the lack of heparin binding by RCP. Moreover, we do not notice other highly positively charged regions at the surface of RCP, which are the zones usually required for heparin binding (26) , confirming further the above reported experimental data. A probe-mapping algorithm was used to investigate the exact same region (interface between the CCP1 and CCP2) of KCP and RCP (Fig. 8B) . This approach predicts the reactive regions where a small molecule could most likely bind with sufficient affinity. Because heparin molecules interact with proteins essentially via electrostatic interactions (although other types of interactions can be important), only the probes representing hot spots for hydrogen bond formation were presented in Fig. 8B . On KCP, a nearly linear and proberich region was observed at the CCP1-CCP2 interface. There, an almost extended heparin molecule could bind, which has been confirmed experimentally (12) . However, for RCP, the potentially reactive region is much smaller and only involves a minute portion of the CCP1 surface. The linear and extended distribution of positively charged residues seen in KCP is no longer present in RCP, further explaining why this region has no ability to bind heparin.
The KCP and RCP amino acid sequences were aligned, and amino acids critical for CFA, DAA, and C3b/C4b binding of KCP were compared with the amino acids in RCP-H at corresponding sites (Table 1 ). The aforementioned residues Arg-20 and Arg-33 in KCP have also been shown to play a role in classical DAA and C4b binding (8) . However, the other known critical amino acids within these sites show functional homology or similarity. Exceptions are Glu-99 in KCP, which aligns with Thr in RCP-H, and Lys-131, which aligns with Ile (however, these pairs share some physicochemical properties, according to the Venn diagram (27) ). Unexpectedly, within the amino acid residues located in CCP4 of KCP that are critical for C3b binding, only His-213 is conserved in RCP-H. This difference suggests that RCP-H has an entirely different binding site for C3b that is missing in KCP.
DISCUSSION
There are only a limited number of reports investigating the pathogenic importance of viral complement inhibitors. However, the existing reports for monkeypox virus (28), herpes simplex virus 1 (29, 30) , and murine gammaherpesvirus 68 (31) suggest that such mechanisms of evading this aspect of the host immune response are critical for virus infectivity, spread, and outcome of related diseases.
By analogy to complement inhibitors of viruses mentioned above, KCP likely plays a role in infection and disease progression. One can follow the anti-KCP immune response in man (32) and assess its eventual prognostic value; however, the role of KCP in pathogenesis cannot be addressed directly. Studies using the related gammaherpesvirus RRV may provide this opportunity. In this study we have found RCP to be a functional homolog of KCP at the level of regulating complement activation. Our studies reveal that RCP variants cloned from two different strains of RRV were as effective as KCP in supporting degradation of C3b and C4b by FI. The activity of FI is tightly regulated as it can exert proteolytic activity only on C3b and C4b after their conformation has been changed through binding of a cofactor, such as KCP or RCP. The ability of RCP vari-FIGURE 6. RCP-mediated decay of the classical and alternative C3/C5 convertase. The ability of RCPs to accelerate decay of C3/C5 convertases was analyzed with hemolytic assays. Sheep erythrocytes bearing particular convertase complex assembled stepwise from purified components were exposed to RCPs (or KCP as a reference) and then incubated with guinea pig serum (C3 convertase) or a mix of purified C5-C9 proteins (C5 convertase) to undergo membrane attack complex-mediated lysis for 60 min. Afterward, hemoglobin released into the supernatant was measured at 405 nm. A shows decay acceleration of the classical C3 convertase, and B shows decay acceleration of the alternative C3 convertase. Decay acceleration of classical and alternative C5 convertase is presented in C and D, respectively. Results are presented as % of control (no inhibitor added). Data presented as means Ϯ S.D. are collected from three independent experiments. Statistical significance between particular protein/concentration and control readout was assessed by Student's t test for unpaired data, where * ϭ p Ͻ 0.05; ** ϭ p Ͻ 0.01; *** ϭ p Ͻ 0.001. ants to accelerate decay of the classical C3 convertase was also similar to that of KCP. However, RCP-H was weaker and RCP-1 was stronger than KCP for this function. It is worth noting that RCP-1 showed the strongest binding to C4b, out of all proteins tested, likely directly related to its doubled binding sites and superior decay accelerating activity. Surprisingly, RCP-1 was also highly effective in accelerating decay of the alternative C3 convertase, which makes it fairly unique among the viral complement inhibitors; the activity of KCP and RCP-H was negligible, and previous reports have only shown very weak alternative DAA for VCP and complement control protein homolog (CCPH) encoded by herpesvirus saimiri (33) . However, the lower activity observed for the CCP5-8 portion suggests that the naturally occurring shorter isoform for strain 17577 (19) would be less effective than the full-length RCP. Accordingly, RCP-1 also bound to C3b, more strongly than the other RCP/ KCP variants. However, a positive correlation between the ability to bind C3b/C4b and the ability of a given protein to accelerate decay has yet to be demonstrated. RCP-1 bound C3b and C4b the strongest, and it was the best inhibitor of both convertases. On the other hand, although KCP and RCP-H are able to interact with C3b, they are not able to accelerate decay of the alternative C3 convertase. One explanation is that alternative DAA might require a threshold affinity of binding, which is provided by the larger RCP-1 molecule. Substantial inhibition of alternative complement pathway observed in whole serum by other RCP isoforms as well as KCP must therefore stem mainly from their CFA activity, as experiments performed on purified alternative C3 convertase system showed no or little effect. Also, when comparing the results of complement inhibition by KCP/RCP in whole serum to those obtained with purified components, one has to consider possible masking effects by other proteins, competition for ligands by other inhibitors, or contribution of other mechanisms, e.g. those taking place beyond C3 convertase.
One interesting difference between KCP and RCP is their binding to heparin. KCP binds to heparin and heparan sulfate (12) and in the current experiment KCP bound readily to a heparin-Sepharose column and was eluted with a salt concentration higher than the physiological NaCl concentration. Under the same conditions, most of the RCP was unbound for all variants tested. We have previously suggested that KCP may be involved not only in protecting viral particles and infected cells from complement, but also in attachment of KSHV to its target cells (12, 13) , because it is expressed on the virion surface (13) . Therefore, RCP may lack one important function of KCP, and in vivo experiments with RRV lacking RCP will specifically assess only the role of viral complement inhibitors of RCP as immune regulators. Furthermore, RCP is the first complement inhibitor described to date that is not able to bind heparin, negating a hypothesis that structural properties of binding sites for C3b and C4b inadvertently create interaction sites for heparin (34) . Therefore, binding of heparin is obviously a specific event for these inhibitors.
Much is known about structure-function relationships in KCP at the amino acid level (reviewed in Ref. 35) . Because RCP and KCP share near 50% identity, some structural motifs could be retained between these two proteins. Also, overall folding of CCP domains is highly conserved. In KCP, residues critical for cofactor function are localized to the hinge region of CCP1 and CCP2 and also between CCP2 and CCP3 (8) . Additionally, C3b cleavage required amino acids located in CCP4. In addition to the residues required for DAA, two residues in CCP2 and three residues in CCP3 were required to mediate CFA (8) . Moreover, analysis of RCP-1 fragments revealed that both of them retain cofactor and decay acceleration functions when expressed independently. Such observations lead us to suggest that this protein could stem from duplication of a similar, highly conserved four CCP domain precursor unit for both RRV strains. Interestingly, the heparin-binding site of KCP was reported to overlap with the CCP1/CCP2 hinge region critical for complement-inhibitory function (12), whereas RCP com-FIGURE 8. Models of KCP and RCP proteins. A, KCP and RCP models are shown in a solid surface representation color-coded according to the nature of the amino acids (the side chains of positively charged residues, blue; of negatively charged residues, red; hydrophobic and aromatic residues, yellow; and remaining atoms and backbone atoms, green). The two models are shown in a manner that highlights the heparin-binding site of KCP (i.e. the negatively charged heparin polymer is symbolized by a red dotted line). The inserted loop in RCP as compared with KCP, which could also perturb heparin binding, is visible at the CCP1-CCP2 interface, where it protrudes into the solvent (i.e. the convex surface to the right of the figure at the same level than the heparin label). B, two models are shown in a solid surface presentation (magenta), and the energetic probes (computed only for the CCP1-CCP2 interface) highlighting regions able to form energetically favorable electrostatic interactions are shown as blue spheres. For KCP, the interface is dense with probes, and the zone extends from CCP1 to CCP2, forming the most likely region able to bind directly with the negatively charged heparin molecules, which has been confirmed experimentally. The equivalent area of RCP is less dense with probes, and a linear and extended distribution of positively charged amino acids able to form hydrogen bonds and salt bridges with the heparin molecule is lacking. This observation together with the lack of other electropositive regions at the surface of RCP and the inserted loop at the CCP1-CCP2 interface support the presently reported experimental data, i.e. RCP should not be a good heparin partner. C, alignment of the KCP and RCP-H sequences, starting with the first cysteine in CCP1 and ending with the fourth cysteine in CCP4; the numbering relates to the KCP sequence. Amino acids found to be critical for particular complement-related functions in KCP (see Table 1 and Ref. pletely lacks heparin binding. Importantly, the ability of RCP to bind C3b/C4b, but not heparin, shows that these two binding abilities are not just a nonspecific coincidence related to the presence of a patch of positively charged amino acids. Based on our three-dimensional model of RCP-H and on structural analysis/binding site prediction via probe mapping computations of this region (Fig. 8) , we conclude that the absence of Arg-20 and Arg-33, together with the presence of an extended loop around the CCP1/CCP2 hinge impairs heparin binding. Although these two missing Arg residues are also engaged in DAA and C4b binding by KCP, these functions are preserved in RCP. Our explanation is that DAA and C4b-binding functional sites are extended to other CCP domains, and thus overall interaction could be retained because of the presence of other conserved amino acids, whereas the heparin-binding site is narrowed to a patch of positively charged amino acids in the CCP1/CCP2 hinge so that even a small change can critically influence necessary interactions. A similar heparin-binding site that was located at the narrow interface of the two N-terminal CCP domains was identified in VCP (36) and C4BP (37) . Interestingly, the heparin-binding site in C4BP contains also three Arg residues, and mutation of a single one significantly decreased affinity to heparin; this effect was markedly enhanced by a double mutation (37) further supporting the idea that the two positively charged residues missing on RCP as compared with KCP explain in part the lack of interaction with heparin, whereas the protruding loop in this region could impede further the interaction with this negatively charged polymer.
Comparing KCP and RCP with other viral complement inhibitors such as VCP, CCPH (33) , and smallpox inhibitor of complement enzymes (38) , which all consist of four CCP domains, some similarities can be found as follows: (i) all of them act as cofactors for C3b and C4b cleavage by FI; (ii) all but RCP-1 exhibit decay acceleration activity for the classical pathway that is much stronger than that for the alternative pathway (if such activity can at all be detected); and (iii) inhibitors with a single binding site have lower DAA than those with double/ multiple binding sites, as shown for CR1 and C4BP compared with smallpox inhibitor of complement enzymes and VCP (39) or CR1 and factor H compared with CCPH and VCP (33) . This observation also holds true for RCP-1, which dissociated convertases more effectively than its 4-CCP domain subunits or homolog RCP-H.
Taken together, our studies show that RCP retains all of the complement inhibitory functions found in KCP. RCP-1 variant has the additional ability to accelerate decay of the alternative C3 convertase. These results provide strong rationale for constructing an RCP-null recombinant RRV to investigate the role of complement evasion in infection and pathogenesis in a rhesus macaque primate model and to evaluate anti-RCP and -KCP therapeutic strategies.
